# InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/IFRX/inflarx-announces-participation-in-the-leerink-partners-global-healthcare-confer-480871ef
Ticker: IFRX
Company: Inflarx NV
Source: Inflarx NV
Published: 2026-02-26 12:30 EST
## Summary

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by...

## Article Body
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Leerink Partners Global Healthcare Conference. Details are as follows:

Leerink Partners Global Healthcare Conference March 8 - 11, 2026 in Miami, FL Fireside chat on March 9 at 9:20 AM ET

InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the fireside chat live stream and its replay is available here .

About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS). The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de . InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

| InflaRx N.V. | MC Services AG |
| --- | --- |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |

FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
## Recent Company News
- 2026-06-30 11:30 EST — [InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos](https://biopharmsignal.com/news/IFRX/inflarx-assessing-feasibility-of-broadened-strategy-for-anca-associated-vasculit-7f39d900) — Source: Inflarx NV
- 2026-05-08 12:15 EST — [InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares](https://biopharmsignal.com/news/IFRX/inflarx-announces-closing-of-150-million-underwritten-offering-of-ordinary-share-085761a8) — Source: Inflarx NV
- 2026-05-06 12:30 EST — [InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares](https://biopharmsignal.com/news/IFRX/inflarx-announces-pricing-of-150-million-underwritten-offering-of-ordinary-share-36e34ae6) — Source: Inflarx NV
- 2026-05-06 12:25 EST — [InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases](https://biopharmsignal.com/news/IFRX/inflarx-announces-advancement-of-izicopan-in-anca-associated-vasculitis-and-sele-3cdb784a) — Source: Inflarx NV
- 2026-05-04 11:30 EST — [InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes](https://biopharmsignal.com/news/IFRX/inflarx-reports-favorable-reactive-metabolite-profile-for-izicopan-in-human-live-6c0b8eb5) — Source: Inflarx NV
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)